A Head-to-Head Comparison of Four Artemisinin-Based Combinations for Treating Uncomplicated Malaria in African Children: A Randomized Trial

English version České info

Background:
Artemisinin-based combination therapies (ACTs) are the mainstay for the management of uncomplicated malaria cases. However, up-to-date data able to assist sub-Saharan African countries formulating appropriate antimalarial drug policies are scarce.

Methods and Findings:
Between 9 July 2007 and 19 June 2009, a randomized, non-inferiority (10% difference threshold in efficacy at day 28) clinical trial was carried out at 12 sites in seven sub-Saharan African countries. Each site compared three of four ACTs, namely amodiaquine-artesunate (ASAQ), dihydroartemisinin-piperaquine (DHAPQ), artemether-lumefantrine (AL), or chlorproguanil-dapsone-artesunate (CD+A). Overall, 4,116 children 6–59 mo old with uncomplicated Plasmodium falciparum malaria were treated (1,226 with AL, 1,002 with ASAQ, 413 with CD+A, and 1,475 with DHAPQ), actively followed up until day 28, and then passively followed up for the next 6 mo. At day 28, for the PCR-adjusted efficacy, non-inferiority was established for three pair-wise comparisons: DHAPQ (97.3%) versus AL (95.5%) (odds ratio [OR]: 0.59, 95% CI: 0.37–0.94); DHAPQ (97.6%) versus ASAQ (96.8%) (OR: 0.74, 95% CI: 0.41–1.34), and ASAQ (97.1%) versus AL (94.4%) (OR: 0.50, 95% CI: 0.28–0.92). For the PCR-unadjusted efficacy, AL was significantly less efficacious than DHAPQ (72.7% versus 89.5%) (OR: 0.27, 95% CI: 0.21–0.34) and ASAQ (66.2% versus 80.4%) (OR: 0.40, 95% CI: 0.30–0.53), while DHAPQ (92.2%) had higher efficacy than ASAQ (80.8%) but non-inferiority could not be excluded (OR: 0.35, 95% CI: 0.26–0.48). CD+A was significantly less efficacious than the other three treatments. Day 63 results were similar to those observed at day 28.

Conclusions:
This large head-to-head comparison of most currently available ACTs in sub-Saharan Africa showed that AL, ASAQ, and DHAPQ had excellent efficacy, up to day 63 post-treatment. The risk of recurrent infections was significantly lower for DHAPQ, followed by ASAQ and then AL, supporting the recent recommendation of considering DHAPQ as a valid option for the treatment of uncomplicated P. falciparum malaria.

Trial Registration: ClinicalTrials.gov NCT00393679; Pan African Clinical Trials Registry PACTR2009010000911750

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: A Head-to-Head Comparison of Four Artemisinin-Based Combinations for Treating Uncomplicated Malaria in African Children: A Randomized Trial. PLoS Med 8(11): e32767. doi:10.1371/journal.pmed.1001119
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001119

Souhrn

Zdroje

1. Prudhomme O'MearaWNekesa MangeniJSteketeeRGreenwoodB 2010 Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect Dis 10 545 555

2. World Health Organization 2009 World malaria report 2009 Geneva World Health Organization

3. SharpBLKleinschmidtIStreatEMaharajRBarnesKI 2007 Seven years of regional malaria control collaboration—Mozambique, South Africa, and Swaziland. Am J Trop Med Hyg 76 42 47

4. SharpBLRidlFCGovenderDKuklinskiJKleinschmidtI 2007 Malaria vector control by indoor residual insecticide spraying on the tropical island of Bioko, Equatorial Guinea. Malar J 6 52

5. NyarangoPMGebremeskelTMebrahtuGMufundaJAbdulmuminiU 2006 A steep decline of malaria morbidity and mortality trends in Eritrea between 2000 and 2004: the effect of combination of control methods. Malar J 5 33

6. BhattaraiAAliSSKachurSPMårtenssonAAbbasAK 2007 Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med 4 e309 doi:10.1371/journal.pmed.0040309

7. FeganGWNoorAMAkhwaleWSCousensSSnowRW 2007 Effect of expanded insecticide-treated bednet coverage on child survival in rural Kenya: a longitudinal study. Lancet 370 1035 1039

8. NostenFWhiteNJ 2007 Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 77 Suppl 6 181 192

9. BosmanAMendisKN 2007 A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am J Trop Med Hyg 77 Suppl 6 193 197

10. BathurstIHentschelC 2006 Medicines for Malaria Venture: sustaining antimalarial drug development. Trends Parasitol 22 301 307

11. D'AlessandroU 2009 Existing antimalarial agents and malaria-treatment strategies. Expert Opin Pharmacother 10 1291 1306

12. World Health Organization 2010 Guidelines for the treatment of malaria, 2nd edition Geneva World Health Organization

13. Medicine for Malaria Venture 2007 Orphan drug status for MMV drug DHA-piperaquine. Available: http://www.mmv.org/newsroom/news/orphan-drug-status-mmv-drug-dha-piperaquine. Accessed 12 December 2010

14. BassatQMulengaMTintoHPiolaPBorrmannS 2009 Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS ONE 4 e7871 doi:10.1371/journal.pone.0007871

15. ValechaNPhyoAPMayxayMNewtonPNKrudsoodS 2010 An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS ONE 5 e11880 doi:10.1371/journal.pone.0011880

16. World Health Organization 2010 Global report on antimalarial drug efficacy and drug resistance: 2000–2010 Geneva World Health Organization

17. LuzzattoL 2010 The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics. Lancet 376 739 741

18. World Health Organization Communicable Diseases Cluster 2000 Severe falciparum malaria. Trans R Soc Trop Med Hyg 94 Suppl 1 S1 S90

19. World Health Organization 2008 Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations Geneva World Health Organization

20. PloweCVDjimdeABouareMDoumboOWellemsTE 1995 Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 52 565 568

21. World Health Organization 2003 Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria Geneva World Health Organization

22. StepniewskaKTaylorWRMayxayMPriceRSmithuisF 2004 In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother 48 4271 4280

23. EngelsEASchmidCHTerrinNOlkinILauJ 2000 Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses. Stat Med 19 1707 1728

24. NewcombeRG 1998 Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 17 873 890

25. PremjiZUmehREOwusu-AgyeiSEsamaiFEzedinachiEU 2009 Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: A randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. PLoS ONE 4 e6682 doi:10.1371/journal.pone.0006682

26. TshefuAKGayeOKayentaoKThompsonRBhattKM 2010 Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 375 1457 1467

27. NdiayeJLRandrianarivelojosiaMSagaraIBrasseurPNdiayeI 2009 Randomized, multicentre assessment of the efficacy and safety of ASAQ—a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar J 8 125 doi:10.1186/1475-2875-8-125

28. FayeBOffiananATNdiayeJLTineRCToureW 2010 Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast. Trop Med Intern Health 15 608 613

29. DorseyGStaedkeSClarkTDNdjama-MeyaDNzarubaraB 2007 Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 297 2210 2219

30. ClarkTDNjama-MeyaDNzarubaraBMaiteki-SebuguziCGreenhouseB 2010 Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children. PLoS ONE 5 e11759 doi:10.1371/journal.pone.0011759

31. MutabingwaTKAnthonyDHellerAHallettRAhmedJ 2005 Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 365 1474 1480

32. DouglasNMAnsteyNMAngusBJNostenFPriceRN 2006 Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 10 405 416

33. SimpsonJAHughesDManyandoCBojangKAaronsL 2006 Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. Br J Clin Pharmacol 61 289 300

34. OkelloPEVan BortelWByaruhangaAMCorrewynARoelantsP 2006 Variation in malaria transmission intensity in seven sites throughout Uganda. Am J Trop Med Hyg 75 219 225

35. ArinaitweESandisonTGWanziraHKakuruAHomsyJ 2009 Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis 49 1629 1637

36. StepniewskaKWhiteNJ 2008 Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother 52 1589 1596

37. SmithuisFKyawMKPheOAyeKZHtetL 2006 Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet 367 2075 2085

38. GrandeTBernasconiAErhartAGamboaDCasapiaM 2007 A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS ONE 2 e1101 doi:10.1371/journal.pone.0001101

39. MensPFSawaPvan AmsterdamSMVersteegIOmarSA 2008 A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malar J 7 237 doi:10.1186/1475-2875-7-237

40. RatcliffASiswantoroHKenangalemEMaristelaRWuwungRM 2007 Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 369 757 765

41. SmithuisFKyawKMPheOWinTAungPP 2010 Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 10 673 681

42. OuédraogoALBousemaTSchneiderPde VlasSJIlboudo-SanogoE 2009 Substantial contribution of submicroscopical Plasmodium falciparum gametocyte carriage to the infectious reservoir in an area of seasonal transmission. PLoS ONE 4 e8410 doi:10.1371/journal.pone.0008410

43. BousemaTJSchneiderPGouagnaLCDrakeleyCJTostmannA 2006 Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis 193 1151 1159

44. OkellLCDrakeleyCJGhaniACBousemaTSutherlandCJ 2008 Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials. Malar J 7 125 doi:10.1186/1475-2875-7-125

45. ShekalagheSAter BraakRDaouMKavisheRvan den BijllaardtW 2010 In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (g6pd a−) individuals. Antimicrob Agents Chemother 54 1762 1768

46. TintoHSanouBErhartAD'AlessandroUOuédraogoJB 2006 In vivo sensitivity of Plasmodium falciparum to chloroquine and sulfadoxine-pyrimethamine in the Bobo Dioulasso region (1998–2001): risk factors associated with treatment failures to the two drugs. Bull Soc Pathol Exot 99 161 165

47. BorrmannSBinderRKAdegnikaAAMissinouMAIssifouS 2002 Reassessment of the resistance of Plasmodium falciparum to chloroquine in Gabon: implications for the validity of tests in vitro vs. in vivo. Trans R Soc Trop Med Hyg 96 660 663

48. LellBLehmanLGSchmidt-OttJRSturchlerDHandschinJ 1998 Malaria chemotherapy trial at a minimal effective dose of mefloquine/sulfadoxine/pyrimethamine compared with equivalent doses of sulfadoxine/pyrimethamine or mefloquine alone. Am J Trop Med Hyg 58 619 624

49. EzedinachiE 1996 In vivo efficacy of chloroquine, halofantrine, pyrimethamine-sulfadoxine and ginghaosu (artesunate) in the treatment of malaria in Calabar, Nigeria. Cent Afr J Med 42 109 111

50. MulengaMMalungaPBennettSThumaPShulmanC 2006 Folic acid treatment of Zambian children with moderate to severe malaria anemia. Am J Trop Med Hyg 74 986 990

51. TintoH 2005 Plasmosium falciparum drug resistance: molecular markers, in vivo and in vitro tests [PhD dissertation] Antwerp University of Antwerp

52. TalisunaAOLangiPBakyaitaNEgwangTMutabingwaTK 2002 Intensity of malaria transmission, antimalarial-drug use and resistance in Uganda: what is the relationship between these three factors? Trans R Soc Trop Med Hyg 96 310 317

53. TalisunaAOOkelloPEErhartACoosemansMD'AlessandroU 2007 Intensity of malaria transmission and the spread of Plasmodium falciparum resistant malaria: a review of epidemiologic field evidence. Am J Trop Med Hyg 77 Suppl 6 170 180

54. AlonsoPLSacarlalJAponteJJLeachAMaceteE 2004 Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364 1411 1420

55. AbacassamoFEnosseSAponteJJGómez-OlivéFXQuintóL 2004 Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. Trop Med Int Health 9 200 208

56. LegrosDJohnsonKHoupikianPMakangaMKabakyengaJK 2002 Clinical efficacy of chloroquine and sulfadoxine-pyrimethamine in children under five from southwestern Uganda with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 96 199 201